New York, New York-- (Newsfile Corp. - March 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. . Shareholders who purchased shares of ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Market ...

In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...

SAN FRANCISCO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial.

On or about September 2024, BioAge conducted its IPO, selling 12.65 million shares of stock for $18 per share. On December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES ...

WHAT'S NEXT? If you suffered a loss in BioAge during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any ...

Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, March 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law ...

BioAge Labs (BIOA) has filed for an upsized 10,500,000 share IPO at $17-$19 per share. The company previously indicated a 7.5M share offering in the same price range.

Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In BioAge To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in BioAge ...

SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2025 / BioAge Labs, Inc. (NASDAQ:BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial.